What Фромилид Уно Treats: Main Uses and Benefits

The primary therapeutic domain of Фромилид Уно (clarithromycin) is considered relevant in contexts involving acute or unstable symptom patterns associated with bacterial infection, which may provide support that helps ease the symptom burden. The medication is commonly used to help with a wide range of conditions where short-term symptomatic assistance is appropriate.

The therapy is relevant in contexts marked by increased discomfort or tension arising from various microbial sources. It is generally applied in addressing symptoms related to inflammatory or irritative states that manifest in conditions involving episodic or fluctuating manifestations.

It is commonly used during phases when symptoms become more noticeable, in situations where patients experience infections, particularly those involving the respiratory tract (such as conditions presenting with symptoms related to physical discomfort), the skin and soft tissue (where symptoms create noticeable functional strain), and is applied in scenarios where additional management of discomfort is required in H. pylori associated conditions.

This supportive approach assists with maintaining functional stability and may contribute to improved comfort during periods of heightened symptoms. It may assist with maintaining functional stability, which helps patients cope more steadily by easing distress.

---

Quick Fact: Relief for Symptoms Related to Inflammatory States

Regulatory References

1. NIH DailyMed official label for Clarithromycin

Eligibility for Фромилид Уно (Clarithromycin Prolonged-Release)

This medication is typically indicated for use in adults and adolescents 12 years of age and older. The prolonged-release tablet formulation is not recommended for children younger than 12 years; for this age group, a paediatric suspension is generally preferred.

---

Absolute Contraindications (Must Not Use)

Patients who must not take Фромилид Уно include those with:

• A known allergy to clarithromycin, erythromycin, or any macrolide antibiotics.
• A history of QT interval prolongation or ventricular cardiac arrhythmias (including Torsades de pointes).
• Severe renal impairment (creatinine clearance less than 30 ml/min), as the dose of the prolonged-release tablet cannot be reduced.
• Severe hepatic failure combined with renal impairment.
• Uncorrected electrolyte disturbances such as low potassium (hypokalaemia).

---

Restricted Use and Special Populations

Population/Condition	Eligibility Status	Restriction Notes
Pregnancy	Not Recommended	Use only if no alternative is appropriate, due to potential fetal risk established in animal studies.
Breastfeeding	Not Recommended	Excreted into breast milk; infant safety has not been established.
Cardiac Conditions	Caution Required	Patients with coronary artery disease or severe cardiac insufficiency require careful assessment due to the risk of QT prolongation.
Organ Impairment	Caution Required	Caution is advised for general hepatic impairment or moderate renal impairment.

Official Regulatory Information on Interactions

Clarithromycin, the active component of this medication, is officially classified as a potent inhibitor of the CYP3A4 isoenzyme. This interaction pattern underlies regulatory restrictions concerning co-administration with numerous other medicinal products.

Formally Contraindicated Combinations

Co-administration is strictly prohibited with several substances due to the risk of serious adverse events caused by markedly increased exposure.

• HMG-CoA Reductase Inhibitors (Statins): Contraindicated with Lovastatin and Simvastatin due to the risk of severe muscle damage, including rhabdomyolysis.
• Cardiac and QT-Prolonging Agents: Contraindicated with Pimozide, Cisapride, Astemizole, and Terfenadine due to the high risk of QT prolongation and life-threatening arrhythmias, such as Torsades de Pointes.
• Ergot Alkaloids: Contraindicated with Ergotamine and Dihydroergotamine due to the risk of acute ergot toxicity.

Other Clinically Significant Interaction Patterns

Concomitant use with Warfarin may result in a risk of serious haemorrhage and elevated International Normalized Ratio (INR). When taken with Insulin or Oral Hypoglycemic Agents, a risk of significant hypoglycemia is documented.

Administration-Related Constraints

The extended-release tablet form must be administered with food to prevent a documented reduction in systemic exposure. If co-administered with Zidovudine, the two medicines must be taken at least 2 hours apart to avoid diminished Zidovudine absorption. Co-administration of Colchicine is strictly prohibited in patients with pre-existing renal or hepatic impairment.

Фромилид Уно operates by selectively inhibiting bacterial protein synthesis. The drug is classified as a macrolide antibiotic and functions by non-covalently binding to the 50S subunit of the bacterial ribosome. This molecular target is situated near the peptidyl transferase center on the large ribosomal subunit.

The binding of Фромилид Уно physically obstructs the peptide exit tunnel, which is necessary for the nascent peptide chain to leave the ribosome. This action blocks the ribosomal translocation process, thereby stalling the elongation phase of protein synthesis and preventing the further assembly of essential bacterial proteins. The consequent systemic physiological effect is bacteriostasis, which is the suppression of proliferation in susceptible bacterial populations. The mechanism is independent of the host immune response and is solely based on the specific interference with the fundamental microbial life cycle.

How to Use Фромилид Уно

The administration of Фромилид Уно (Clarithromycin Extended-Release) is designed to ensure the sustained-release mechanism functions as intended. The standard regimen focuses on a Once Daily usage pattern.

---

Official Administration Guidelines

Instruction	Guideline
Route of Administration	Oral administration of the tablet form only.
Dosing Schedule (Adults)	The standard adult daily dose is 1 gram (1000 mg), administered as two 500 mg extended-release tablets.
Frequency	Once Daily (every 24 hours), which is the standard regimen for this sustained-release formulation.
Intake Condition	The tablets must be taken with food to optimize the rate of absorption.

---

Procedural and Population Constraints

Proper use strictly requires that the tablets be swallowed whole. They must not be chewed, broken, or crushed, as altering the physical form disrupts the controlled-release properties of the medicine. The duration of the treatment course varies, typically lasting between 7 and 14 days, depending on the specific condition being addressed.

For adult patients diagnosed with severe renal impairment (creatinine clearance less than 30 mL/min), a dose modification is required: the total daily dosage must be reduced by 50%. The extended-release form is generally indicated and dosed for the adult population.

Research evidence / Overview of studies for Фромилид Уно

---

Evidence for Acute Respiratory Tract Infections

The primary research base documented for the extended-release formulation of Clarithromycin consists of trials related to acute infections of the respiratory tract. These conditions, such as Acute Bacterial Exacerbation of Chronic Bronchitis (AECB), Acute Maxillary Sinusitis (AMS), and Community-Acquired Pneumonia (CAP), was studied for how symptoms change over defined time intervals.

Researchers conducted Randomized Controlled Trials (RCTs) and gathered Systematic Reviews to explored the measurement of outcomes related to the medicine. These studies primarily examined clinical success rates, or the number of patients who were free of or had major reductions in key symptoms after treatment. They also monitored the rate of bacteriologic clearance, which means tracking the clearance of specific bacteria observed during the infection. The trials predominantly included adult populations presenting with infections that were classified as mild to moderate severity.

---

Research Landscape for Other Infections Addressed by the Active Ingredient

The active ingredient in Фромилид Уно was evaluated in a broader research landscape for other conditions, including Helicobacter pylori associated conditions and certain skin and soft tissue infections. However, research for these specific contexts often involves the immediate-release formulation of Clarithromycin, rather than the extended-release form found in Фромилид Уно. The studies explored various multi-drug regimens relevant to H. pylori clearance and general comparative trials for skin infections, but the evidence is limited for the extended-release formulation itself in these areas.

---

Studies Comparing the Extended-Release and Standard Forms

Given that Фромилид Уно is a specific sustained-release dosage form, a separate line of research has examined the differences between this formulation and the standard, immediate-release tablets. These comparative studies were designed to track whether the less frequent dosing of the extended-release formulation provided a similar level of the active ingredient in the body compared to the more frequent dosing required by the standard tablets. Research highlights changes measured during the study period that helped contextualize the study endpoints related to the active ingredient's release.

---

Key Limitations and Areas of Research Uncertainty

The research contributes to the broader evidence landscape, but also highlights areas where certainty remains low or where more study is needed. The results apply only to the populations studied and are subject to several limitations. One key limitation is the fact that many comparative trials against other antibiotics were designed to assess non-inferiority endpoints. Another significant area of uncertainty is the potential for emerging resistance to macrolide antibiotics, as research is ongoing that tracks this phenomenon in key bacterial strains. Additionally, regulatory labeling emphasizes that the extended-release formulation was studied for the specific adult respiratory infections in the core trials, and regulatory evidence for its application outside of those approved areas has not been fully established.

Key Studies & References

1. CLARITHROMYCIN tablet, film coated, extended release - DailyMed

Common questions about Фромилид Уно (FAQ)

Q: Сколько дней обычно длится курс лечения Фромилид Уно?

According to official product information, the recommended duration for treatment is typically between 7 and 14 days. The exact length of the course is determined by a healthcare provider based on the type and severity of the specific infection being treated.

Q: Можно ли пить алкоголь во время приема Фромилид Уно?

Official drug labels for clarithromycin, the active ingredient, do not specifically list an interaction with alcohol that is strictly prohibited. However, when using any prescription medicine, patients should always consult with their healthcare provider regarding alcohol consumption.

Q: Как Фромилид Уно влияет на печень?

Official regulatory documents indicate that clarithromycin can affect the liver, with common side effects including elevations in liver enzymes (AST/ALT). In rare instances, severe liver failure has been reported. The medicine is officially contraindicated for patients with a history of cholestatic jaundice or liver dysfunction associated with previous macrolide use.

Q: Разрешен ли Фромилид Уно для приема детям?

The extended-release tablets are generally intended for use in adults and adolescents aged 12 years and older. This formulation is not recommended for children under 12 years of age, as a paediatric suspension is usually the preferred method for younger patients.

Q: Что делать, если пропустил прием таблетки Фромилид Уно?

Official guidelines suggest that if a dose is missed, it can be taken as soon as the patient remembers. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should then resume the regular dosing schedule. Double doses should not be taken to make up for a forgotten one.

Q: Какие анализы нужно сдать перед началом приема Фромилид Уно?

While regulatory documents do not mandate routine blood tests for all patients, they do emphasize the importance of checking for conditions like QT prolongation and ensuring any uncorrected electrolyte disturbances (such as low potassium) are managed before starting the medicine. The determination of specific laboratory monitoring rests with the healthcare provider.

Q: Может ли Фромилид Уно повлиять на управление автомобилем?

Official safety information states that the medicine may cause side effects like dizziness, vertigo, confusion, and disorientation, which could potentially impair a patient’s ability to drive or operate machinery. Patients should consider how the medication affects them before driving or operating machinery.

Q: Как долго Фромилид Уно выводится из организма?

Official regulatory documents contain information regarding the elimination half-life of clarithromycin and its metabolites, which is the time it takes for the concentration of the substance to be reduced by half in the body. The half-life is described as prolonged due to the sustained-release nature of the tablet, but an exact individual clearance time is not specified.

Q: Можно ли принимать Фромилид Уно людям с почечной недостаточностью?

The use of the prolonged-release tablets is strictly prohibited in cases of severe renal impairment (creatinine clearance less than 30 mL/min). Caution is also required for individuals with moderate renal impairment.

Q: Влияет ли Фромилид Уно на действие оральных контрацептивов?

Official drug labels for clarithromycin do not list a direct or commonly documented interaction with oral contraceptives that would require a specific warning about reduced effectiveness. Patients are advised to discuss the use of contraceptives and any other medications with their prescribing physician.

Q: Как часто встречаются серьезные побочные эффекты от Фромилид Уно?

The frequency of many serious side effects, such as Torsade de pointes (a serious heart rhythm disturbance) or severe liver failure, is generally categorized in regulatory documents as 'Not Known.' This classification is due to the fact that these rare events are usually derived from voluntary post-marketing reports, which makes estimating their true frequency challenging.

Q: Можно ли принимать Фромилид Уно людям пожилого возраста?

The medicine can be taken by the elderly population. However, official information advises that caution is necessary, particularly to assess and potentially adjust the dose if the patient has pre-existing severe renal impairment, which is a condition often seen in older adults.

Q: Можно ли принимать Фромилид Уно, если принимаешь лекарства от давления?

Official product information highlights significant interactions with certain medications for high blood pressure, specifically calcium channel blockers (like Verapamil, Amlodipine, and Diltiazem). Co-administration with these drugs may increase the risk of adverse events such as low blood pressure. The use of clarithromycin with other anti-hypertensives should be managed by a healthcare provider.

Q: Может ли Фромилид Уно вызвать головокружение?

Yes, regulatory documents list dizziness (vertigo) as a documented uncommon side effect of clarithromycin. If dizziness is experienced, it is recommended to inform a healthcare professional.

Q: Влияет ли Фромилид Уно на сон?

Official information lists somnolence, which means drowsiness, as an uncommon side effect. Some regulatory reports also mention sleep disturbances in the 'Not Known' category. Patients who notice changes in their sleep patterns should discuss this with their healthcare provider.

Q: Как часто встречаются резистентные штаммы к Фромилид Уно?

Regulatory documents indicate that resistance to macrolide antibiotics, including clarithromycin, is a recognized global health concern, and its frequency can vary by location and time. Susceptibility data on specific bacterial strains are included in official labels, but a general, simple frequency estimate of resistance is not provided.

Q: Что такое макролиды, к которым относится Фромилид Уно?

Macrolides are a class of antibiotics to which clarithromycin belongs. They work by targeting the bacteria's ability to create proteins necessary for growth. Specifically, macrolides bind to the bacteria's ribosomal subunit, which effectively stops the process of protein assembly.

Q: Можно ли принимать Фромилид Уно вместе с нестероидными противовоспалительными средствами?

Official regulatory documents do not list a specific interaction between clarithromycin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that results in a formal contraindication or special warning. Patients are advised to inform their healthcare provider about all medicines being taken, including over-the-counter NSAIDs.

Q: Существуют ли ограничения по диете во время приема Фромилид Уно?

Yes, the main restriction is that the tablets must be taken with food. This instruction is necessary to ensure the medicine is properly absorbed into the body. Official labeling does not list other specific dietary restrictions, such as warnings against dairy or other products.

Q: Почему Фромилид Уно отпускается только по рецепту?

As an antibiotic and a powerful drug, this medicine is classified as prescription-only. This requirement is in place due to the risks associated with its potent mechanism, the potential for serious side effects (like heart rhythm issues), and the critical need for medical supervision to help combat the global issue of antibiotic resistance.

Q: Как правильно рассчитать время приема Фромилид Уно?

Since this is a once-daily formulation, the medicine should be taken at approximately the same time every 24 hours. Taking the dose with food at a time of day that is consistent and easy to remember helps maintain the required concentration of the medicine in the body.

Q: Может ли Фромилид Уно вызывать тошноту?

Yes, official regulatory documents list nausea as a common side effect of clarithromycin.

Q: Что делать, если при приеме Фромилид Уно началась диарея?

Diarrhea is a common side effect of this medicine. However, severe or persistent diarrhea requires medical evaluation, as official information warns that it may be a sign of Clostridioides difficile-associated diarrhea (CDAD).

Q: Какие исследования проводились по поводу безопасности Фромилид Уно?

Safety information is gathered from initial clinical trials and continuous post-marketing surveillance to track adverse reactions. Specific safety studies have also been conducted, notably those that examined long-term outcomes for patients with coronary artery disease, which revealed an increased risk of long-term all-cause mortality.

How to Store and Dispose of Фромилид Уно?

The storage and disposal of Фромилид Уно (Clarithromycin Extended-Release tablets) must adhere strictly to official regulatory guidelines to maintain product integrity.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep the tablets protected from light and moisture in the original, tightly closed container.
Prohibited	The tablets must not be refrigerated or frozen.
Safety	Keep the medicine out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Фромилид Уно must be discarded according to official pharmaceutical waste guidelines. The preferred method is typically a medication take-back program. Disposal must follow local environmental requirements and should not be placed into wastewater.